They found that CARM1 and the CARM1 methylation sites on NFIB are crucial for the rapid onset of SCLC and further confirmed that CARM1 methylation of NFIB promotes SCLC development, suggesting CARM1 as a potential therapeutic target for SCLC [87]. This evidence concerns the gene NFIB and small cell lung carcinoma.